PRESS RELEASE
Sustai ed g owth ove the fi st i e mo ths of 2026:Reve ue of €181.8m (+5.6% o a epo ted basis)
- St o g pe fo ma ce f om the PHARMAGEST (+3.1% epo ted) a d AXIGATE LINK (+16.1% epo ted a d +3.9% like-fo -like) Divisio s
- Positive mome tum fo mai te a ce a d subsc iptio eve ue (+7.9% ove the fi st i e mo ths of 2026 a d +7.0% i Q3)
- Co ti ued success of the MEDICAL SOLUTIONS Divisio ‘s ew digital t ai i g offe i g (€5.0m ove i e mo ths), although activity is t aditio ally slowe i Q3
- The AXIGATE LINK a d MEDICAL SOLUTIONS Divisio s a e expected to begi Ségu Wave 2 deployme ts i Q4 2026
Ville s-lès-Na cy, 29 Octobe 2026, 18:00 CET – Equase s (ISIN: FR0012882389 – Ticke : EQS), a leadi g p ovide of digital solutio s fo healthca e p ofessio als, today a ou ced eve ue of €181.8m fo the fi st i e mo ths of 2026, up 5.6% o a epo ted basis a d 0.9% like-fo -like.
| G oup eve ue at 30/09/2026 (€m) | 2025Repo ted basis | 2026Repo ted basis | Cha ge / Repo ted basis | Of which exte al g owth | Of which Ségu Wave 2 | Like-fo -like cha ge(o ga ic g owth) | Q1 | 57.1 | 61.4 | 4.4 | 7.7% | 2.5 | 0.2 | 1.7 | 2.9% | Q2 | 58.9 | 63.0 | 4.1 | 6.9% | 3.8 | 0.4 | – | 0.0% | Q3 | 56.2 | 57.3 | 1.1 | 2.0% | 1.1 | 0.2 | -0.2 | -0.2% | Total 9 mo ths | 172.2 | 181.8 | 9.6 | 5.6% | 7.4 | 0.8 | 1.5 | 0.9% |
G oup eve ue be efited f om a positive scope effect of €7.4m, esulti g f om the i teg atio of the activities of EREVO (MEDICAL SOLUTIONS Divisio ), NOVAPROVE a d the acqui ed DIS busi ess (AXIGATE LINK Divisio ). This co t ibutio is excluded f om the calculatio of like-fo -like g owth.
Reve ue f om Wave 2 of the Ségu p og amme amou ted to €0.8m ove the fi st i e mo ths of 2026 (AXIGATE LINK Divisio ). The R&D a d se vices teams ac oss the G oup’s busi ess divisio s a e focused o developi g ew fu ctio alities to fu the e ha ce custome s’ softwa e solutio s. Although ge e ated by the G oup’s existi g ope atio s, eve ue associated with Wave 2 of the Ségu p og amme falls outside the o di a y cou se of busi ess a d, fo that easo , is excluded f om the calculatio of like-fo -like g owth.
De is Supplisso , Chief Executive Office of Equase s, comme ted: “Ove the fi st i e mo ths of the yea , the G oup delive ed a solid pe fo ma ce. The PHARMAGEST a d AXIGATE LINK Divisio s co ti ued to g ow, be efiti g otably f om st o g mome tum i Italy a d sustai ed like-fo -like gai s i the Hospital segme t. The E-CONNECT a d MEDICAL SOLUTIONS Divisio s faced mo e challe gi g co ditio s, a d ew offe i gs have bee lau ched to help esto e g owth. Mo e b oadly, a tificial i tellige ce is a majo focus of ou oadmap, both i the solutio s we develop a d i ou ta geted pa t e ships. With Ségu Wave 2 ampi g up i the fou th qua te , we emai focused o buildi g sales mome tum i the fi al mo ths of 2026 a d layi g the g ou dwo k fo fu the g owth i 2027.”
Reve ue fo the fi st i e mo ths a d Q3 2026 by busi ess segme t
| REVENUE AT 30/09/2026 / BUSINESS SEGMENT (€M) | 2025Repo ted basis | 2026Repo ted basis | Cha ge / Repo ted basis | Systems a d equipme t | 69.3 | 67.7 | -1.6 | -2.3% | Mai te a ce a d subsc iptio s | 77.9 | 84.1 | 6.2 | 7.9% | Softwa e a d se vices | 25.0 | 30.0 | 5.0 | 20.2% | Total | 172.2 | 181.8 | 9.6 | 5.6% |
| Q3 2026 REVENUE / BUSINESS SEGMENT (€M) | 2025Repo ted basis | 2026Repo ted basis | Cha ge / Repo ted basis | Systems a d equipme t | 22.1 | 20.7 | -1.4 | -6.5% | Mai te a ce a d subsc iptio s | 26.5 | 28.3 | 1.9 | 7.0% | Softwa e a d se vices | 7.6 | 8.3 | 0.7 | 9.4% | Total | 56.2 | 57.3 | 1.1 | 2.0% |
Systems a d equipme t sales totalled €67.7m ove the fi st i e mo ths of 2026, a dec ease of €1.6m (-2.3%). Pe fo ma ce va ied ac oss divisio s, with g owth i PHARMAGEST (+1.8%) co t asti g with a sha p decli e i E-CONNECT’s mobility solutio s busi ess (-€2.6m).
Mai te a ce a d subsc iptio sales ose by €6.2m to €84.1m ove the fi st i e mo ths of 2026 (+7.9%), i cludi g a €1.9m co t ibutio i the fi st half f om the acquisitio s of NOVAPROVE a d the DIS busi ess. Q3 g owth of 7.0% was 100% o ga ic.
Softwa e a d se vices eve ue eached €30.0m ove the fi st i e mo ths of 2026, a i c ease of €5.0m (+20.2%). This g owth was d ive by the i teg atio of EREVO’s busi ess.
Reve ue fo the fi st i e mo ths a d Q3 2026 by Divisio
| REVENUE AT 30/09/2026 / DIVISION (€M) | 2025Repo ted basis | Repo ted basis 2026 | Cha ge / Repo ted basis | Of which exte al g owth | Of which Ségu Wave 2 | Like-fo -like cha ge(o ga ic g owth) | PHARMAGEST | 126.6 | 130.5 | 3.9 | 3.1% | 3.9 | 3.1% | AXIGATE LINK | 25.3 | 29.4 | 4.1 | 16.1% | 2.4 | 0.8 | 1.0 | 3.9% | E-CONNECT | 11.4 | 8.7 | -2.7 | -23.4% | -2.7 | -23.4% | MEDICAL SOLUTIONS | 7.4 | 11.9 | 4.5 | 60.9% | 5.0 | -0.5 | -6.8% | FINTECH | 1.5 | 1.2 | -0.3 | -17.2% | -0.3 | -17.2% | Total | 172.2 | 181.8 | 9.6 | 5.6% | 7.4 | 0.8 | 1.5 | 0.9% |
| Q3 2026 REVENUE / DIVISION (€M) | 2025Repo ted basis | Repo ted basis 2026 | Cha ge / Repo ted basis | Of which exte al g owth | Of which Ségu Wave 2 | Like-fo -like cha ge(o ga ic g owth) | PHARMAGEST | 40.7 | 41.5 | 0.8 | 2.1% | 0.8 | 2.1% | AXIGATE LINK | 8.9 | 9.6 | 0.7 | 8.2% | 0.2 | 0.5 | 6.1% | E-CONNECT | 3.9 | 2.5 | -1.4 | -34.9% | -1.4 | -34.9% | MEDICAL SOLUTIONS | 2.3 | 3.3 | 1.0 | 43.7% | 1.1 | -0.1 | -2.2% | FINTECH | 0.5 | 0.4 | -0.1 | -24.8% | -0.1 | -24.8% | Total | 56.2 | 57.3 | 1.1 | 2.0% | 1.1 | 0.2 | -0.2 | -0.2% |
The PHARMAGEST Divisio co ti ued to g ow, with eve ue up 3.1% o a like-fo -like basis to €130.5m i the fi st i e mo ths of 2026. Q3 2026 eve ue amou ted to €41.5m (+2.1%).
I F a ce, eve ue i c eased by 3.6% to €113.1m, maki g it the la gest co t ibuto to the Divisio ‘s g owth. This pe fo ma ce was suppo ted by a comp ehe sive softwa e offe i g cove i g automated p esc iptio e t y, pha macy ma ageme t tools, i ve to y optimisatio , data secu ity a d elect o ic i voici g th ough DIGIPHARMACIE’s app oved platfo m, i cludi g i teg atio with accou ti g softwa e, togethe with equipme t tailo ed to healthca e p ofessio als’ eeds. ASCA, the subsidia y specialisi g i elect o ic shelf labels fo pha macies, mai tai ed its positive mome tum, with eve ue up 5.8%. The i cide t at the G oup’s head office a d sto age facility o 21 Septembe 2026 had o impact o Q3 busi ess, as i stallatio s co ti ued usi g equipme t al eady delive ed to custome s a d stock available at the G oup’s othe logistics sites.
I Italy, g owth accele ated, with eve ue up 6.6% to €11.7m, suppo ted by a pa ticula ly st o g thi d qua te (+12.3% to €3.6m). Busi ess with pha maceutical full-li e wholesale s emai ed at a high level (€8.2m, dow 2.6%) as Eu opea egulatio s o medici e t aceability a d pha maceutical supply chai secu ity we e bei g impleme ted. The pha macy a d pa apha macy segme t eco ded a othe st o g i c ease i eve ue (+38.1% to €3.5m), d ive by sustai ed ew custome acquisitio .
I Ge ma y, eve ue decli ed by 11.2% to €4.1m. The ew softwa e fo Ge ma pha macies was u veiled ahead of its lau ch at the Expopha m exhibitio i Mu ich i Septembe . The sales o ga isatio is bei g established, with fi st sales expected i Q2 2027.
I Belgium, eve ue fell by 13.2% to €1.6m as pha macists became i c easi gly cautious about i vestme t, focusi g i stead o imp ovi g the p ofitability of thei pha macies.
The AXIGATE LINK Divisio eco ded eve ue of €29.4m ove the fi st i e mo ths of 2026, up 16.1% o a epo ted basis a d 3.9% like-fo -like. Q3 2026 eve ue amou ted to €9.6m, ep ese ti g g owth of 8.2% epo ted a d 6.1% like-fo -like.
The Nu si g Home segme t eco ded modest g owth (+0.7% to €12.6m), suppo ted by the additio of ew facilities a d the mig atio of existi g custome s to the Tita Li k SaaS solutio . The ESMS Numé ique fu di g p og amme, which has suppo ted busi ess activity i ece t yea s, will e d i 2026. The Ségu Wave 2 ce tificatio p ocess is also u de way, with ce tificatio expected by the e d of 2026.
The Hospital segme t eco ded eve ue g owth of 81.8% to €7.2m, i cludi g a €2.4m co t ibutio f om ResU ge ces softwa e a d DIS hospital fi a cial ma ageme t solutio s. The impact of these acquisitio s o the scope of co solidatio was limited to the fi st half of 2026. Like-fo -like g owth emai ed pa ticula ly st o g at 22.7%. HospiLi k ow e joys st o g visibility i its ma ket, ge e ati g ume ous sales oppo tu ities. The Ségu ce tificatio s have bee obtai ed, allowi g deployme ts to begi i Q4 2026.
The Home Ca e segme t co ti ued to g ow (+10.0% to €6.4m), suppo ted by the lau ch of Wave 2 of the Ségu p og amme. This g owth is expected to co ti ue, suppo ted by the ew Se vices Auto omie Domicile (home ca e a d suppo t se vices) offe i g a d the pa t e ship with egio al ca e coo di atio e tities (CRT).
The E-CONNECT Divisio epo ted eve ue of €8.7m fo the fi st i e mo ths of 2026, dow 23.4% like-fo -like. Q3 2026 eve ue amou ted to €2.5m, dow 34.9%.
The decli e see i Q2 co ti ued i to Q3, pa ticula ly i mobility solutio s. Dema d f om healthca e p ofessio als a d allied health p ofessio als emai ed weak as pe siste t i flatio a y p essu es p ompted them to defe i vestme t decisio s.
I fixed solutio s, the ew KAP-4CV eade , compatible with both physical Ca te Vitale health i su a ce ca ds a d thei digital equivale ts o sma tpho es, eco ded its fi st sales, with 1,500 u its sold. The eade is desig ed to suppo t the ollout of the Ca te Vitale app by the F e ch atio al health i su a ce system.
The Divisio also faces supply chai p essu es that could i c ease p oductio costs i a al eady challe gi g eco omic e vi o me t. To safegua d its medium-te m p oductio capacity, the Divisio placed o de s fo c itical compo e ts with its supplie s ahead of schedule. Neve theless, it emai s exposed to p ice fluctuatio s a d pote tial sho tages of ce tai compo e ts.
The MEDICAL SOLUTIONS Divisio eco ded eve ue of €11.9m i the fi st i e mo ths of 2026, up 60.9% o a epo ted basis but dow 6.8% like-fo -like. Q3 2026 eve ue amou ted to €3.3m, up 43.7% epo ted a d dow 2.2% like-fo -like.
The Divisio ‘s g owth was d ive by the i teg atio of EREVO, a leadi g F e ch p ovide of digital co ti ui g educatio fo physicia s a d allied health p ofessio als. Despite egulato y u ce tai ty, EREVO successfully developed a ew digital offe i g based o live vi tual class ooms withi just a few mo ths, desig ed to p ovide healthca e p ofessio als with close suppo t th oughout thei t ai i g.
Ove the fi st i e mo ths of 2026, the busi ess ge e ated eve ue of €5.0m, with vi tual class ooms accou ti g fo ea ly 75% of the total. Q3 eve ue of €1.1m was lowe tha i the fi st two qua te s, eflecti g the seaso al atu e of the t ai i g ma ket, whe e activity is t aditio ally slowe du i g the summe .
O a like-fo -like basis, the Divisio eco ded a slight decli e i eve ue amid the eo ga isatio of its dist ibutio etwo k a d the lau ch of ew softwa e offe i gs, otably a patie t applicatio i co po ati g appoi tme t booki g a d medical voice AI.
The featu es developed fo Wave 2 of the Ségu digital healthca e p og amme a e cu e tly u de goi g ce tificatio , with deployme ts scheduled to begi i Q4 2026.
The FINTECH Divisio epo ted eve ue of €1.2m fo the fi st i e mo ths of 2026, dow 17.2% like-fo -like. Q3 2026 eve ue amou ted to €0.4m (-24.8%).
Ma ket co ditio s emai ed u favou able, with fi a ci g ates still high a d volatile.
Outlook
The G oup is p essi g ahead at a sustai ed pace with the i teg atio of a tificial i tellige ce at the co e of its busi ess softwa e, as well as with its R&D i vestme t i age tic AI. The aim is to automate complex p ocesses a d imp ove the p oductivity of healthca e p ofessio als usi g the G oup’s solutio s.
AI is also cha gi g how the G oup wo ks i te ally. Developme t teams have al eady i co po ated AI age ts i to thei p ocesses to imp ove p oductivity, testi g quality a d solutio secu ity.
At the same time, the G oup co ti ues to expa d its SaaS offe i g, suppo ted by secu e hosti g withi Equase s’ p ivate healthca e cloud. Ove time, the comme cialisatio of these ew featu es is i te ded to st e gthe the G oup’s a ual ecu i g eve ue (ARR) a d accele ate its g owth ac oss Eu ope, buildi g o the substa tial mome tum al eady ge e ated by the G oup’s p ese ce i Italy.
The G oup is also expa di g its digital se vices offe i g with EQWO, a solutio combi i g a o li e appoi tme t cale da a d a patie t applicatio to facilitate i te actio s betwee healthca e p ofessio als a d thei patie ts a d st e gthe its positio i digital healthca e.
Withi the MEDICAL SOLUTIONS Divisio , obtai i g CE ma ki g as a medical device fo the biomet ic module of its p actice ma ageme t softwa e ep ese ts a majo milesto e. As the o ly p actice ma ageme t softwa e i F a ce to hold this ce tificatio , it meets mo e st i ge t quality a d safety equi eme ts, fu the st e gthe i g the G oup’s p emium positio i g i the ma ket fo digital solutio s fo healthca e p ofessio als.
Fi ally, secu i g Ségu Wave 2 ce tificatio s fo the G oup’s softwa e, which equi es a substa tial sha e of the G oup’s R&D esou ces, emai s a st ategic p io ity fo the e d of 2026 a d fo FY 2027.
Wo k o the Ségu ce tificatio s a d elated deployme ts is expected to accele ate towa ds yea -e d, subject to the egulato y timetable fo each p og amme segme t.
Fi a cial cale da :
- FY 2026 eve ue p ess elease: 4 Feb ua y 2027
About Equase s G oup
Fou ded ove 40 yea s ago, Equase s G oup, a leade i digital healthca e solutio s, today employs ove 1,500 people ac oss Eu ope. Equase s G oup’s specialised busi ess applicatio s facilitate the day-to-day wo k of healthca e p ofessio als a d thei teams, wo ki g i p ivate p actice, collabo ative medical st uctu es o healthca e establishme ts. The G oup also p ovides comp ehe sive suppo t to healthca e p ofessio als i the t a sfo matio of thei p ofessio by developi g elect o ic equipme t, digital solutio s a d healthca e obotics, as well as data hosti g, fi a ci g a d t ai i g adapted to thei specific eeds. A d eflecti g the spi it of its tagli e “Tech ology fo a Mo e Huma Expe ie ce”, the G oup specialises i i te ope ability solutio s that imp ove coo di atio , commu icatio a d data excha ge amo g healthca e p ovide s, co t ibuti g to bette patie t ca e a d a mo e efficie t a d secu e healthca e system.
Listed o Eu o ext Pa is™ – Compa tme t B
I dexes: MSCI GLOBAL SMALL CAP – GAÏA I dex 2020 – CAC® SMALL a d CAC® All-T adableI cluded i the Eu o ext Tech Leade s segme t a d the Eu opea Risi g Tech label
Eligible fo the Defe ed Settleme t Se vice (“Se vice à Régleme t Diffé é” – SRD) a d equity savi gs accou ts i vested i small a d mid caps (PEA-PME).ISIN: FR 0012882389 – Ticke Code: EQS
Get all the ews about Equase s G oup at www.equase s.com a d o Li kedI
I vesto Relatio s a d Media Co tacts
| Equase s G oupI vesto Relatio s Chief Admi ist ative a d Fi a cial Office F édé ique SchmidtTel.: + 33 (0)3 83 15 90 67f ede ique.schmidt@equase s.com | NewCapI vesto Relatio sThomas G ojea Louis-Victo Delouv ie Tel: + 33 (0)1 44 71 94 94equase s@ ewcap.eu | NewCapFi a cial media elatio sNicolas Mé igeauTel: + 33 (0)1 44 71 94 94equase s@ ewcap.eu |
Fo wa d-looki g stateme ts This p ess elease co tai s fo wa d-looki g stateme ts that a e ot gua a tees of futu e pe fo ma ce a d a e based o cu e t opi io s, fo ecasts a d assumptio s, i cludi g, but ot limited to, assumptio s about Equase s’ cu e t a d futu e st ategy a d the e vi o me t i which Equase s ope ates. These i volve k ow a d u k ow isks, u ce tai ties a d othe facto s that could cause actual esults, pe fo ma ce o achieveme ts, i dust y esults o othe eve ts to diffe f om those desc ibed o p ojected i such fo wa d-looki g stateme ts. These isks a d u ce tai ties i clude those detailed i Chapte 3 “Risk facto s” of the U ive sal Regist atio Docume t filed with the F e ch fi a cial ma ket autho ity (Auto ité des Ma chés Fi a cie s o AMF) o Ap il 29, 2026, u de umbe D.26-0320. These fo wa d-looki g stateme ts a e valid o ly as of the date of this p ess elease.
